The new space race has begun, this time with American and Chinese commercial space companies competing to become the global aerospace industry leader. While these aerospace companies may be looking at the stars, they do not necessarily have their heads in the clouds, as new innovations are benefitting day-to-day life on Earth and increasing public enthusiasm for aerospace technology. While this is a strategic competition for both sides, the rise of privately-owned space companies will ultimately benefit everyone.
Author: Bill Beeson
Is the “Golden Age” of US-China business relations over? With Pat McAloon, director of the Greater Columbus Chinese Chamber of Commerce, and Colin Renk, director of the America China Society of Indiana, we explore US-China business perspectives from a grassroots level in the American Heartland.
China’s biopharmaceuticals is an often overlooked yet quickly growing industry. In recent years, various regulatory reforms have transformed the industry, nurturing it into a global competitor. Many foreign investors are interested in taking advantage of the local industry’s streamlined product registration process and robust development incentives. However, there are still risks that investors should remain cognizant of when planning their entrance strategy into the Chinese biopharmaceutical market.